Vaginitis (Bacterial)MANAGEMENT

GENITOURINARY AND REPRODUCTIVE PRESENTATIONS · 12 SECTIONS

⚲

631 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Acute Kidney Injury (ATN)Acute Kidney Injury (Post-renal)Acute Kidney Injury (Pre-renal)Amniotic Fluid Embolism Balanitis Bladder Rupture Breast Abscess Cystitis Dialysis access complications Ectopic pregnancy Epididymitis Glomerulonephritis Hematuria (gross)Hydrocele Interstitial Cystitis Mastitis Mittelschmerz Nephrolithiasis Nephrotic Syndrome Flare Nutcracker Syndrome Orchitis Ovarian Cyst Rupture Ovarian hyperstimulation syndrome Ovarian torsion Paraphimosis Pelvic Congestion Syndrome Pelvic Inflammatory Disease (PID)Peritoneal dialysis peritonitis Phimosis Priapism Prostatitis Pyelonephritis Renal laceration Renal transplant complications and rejection Ruptured ovarian cyst Testicular torsion Torsion of Appendix Testis Tubo-ovarian abscess Ureteral Rupture Urethritis Urinary Retention Urinary tract infection (uncomplicated)Urolithiasis (renal colic)Vaginal bleeding (non-pregnant)Vaginitis (Bacterial)Vaginitis (Candidal)Varicocele Vulvovaginal Hematoma

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp36

Alarm features and must-not-miss

›Red flag conditions requiring urgent evaluation

›Fever with pelvic pain or cervical motion tenderness

›Suggests PID or tubo-ovarian abscess

›Requires bimanual exam and pelvic ultrasound

›Purulent cervical discharge with WBCs on wet mount

›Cervicitis from chlamydia or gonorrhea until proven otherwise

›NAAT testing mandatory

›Systemic toxicity with hypotension or altered mental status

›Sepsis from ascending gynecologic infection

›Resuscitation and broad spectrum antibiotics within 1 hour

›Bloody or foul-smelling discharge in postmenopausal patient

›Malignancy must be excluded

›Foreign body evaluation

›BV in pregnancy with prior preterm birth history

›2-fold increased risk of preterm birth, PROM, and chorioamnionitis

›Expedite treatment and MFM referral

Key clinical concepts

›Diagnostic framework for BV

›Most common cause of abnormal vaginal discharge in reproductive-age women

›Accounts for 40-50% of identified vaginitis cases

›Approximately 5-10 million office visits annually

›Vaginal dysbiosis, not a true infection or inflammatory condition

›Absence of mucosal inflammation distinguishes BV from vaginitis

›50% of cases are asymptomatic

›Self-diagnosis is unreliable

›ACOG recommends against self-diagnosis due to overlapping symptoms

›Office-based testing or NAAT required for accuracy

02History/hx59

Symptom characterization

›Discharge characteristics

›Thin, homogeneous, grayish-white discharge

›Smoothly coats vaginal walls

›Low viscosity distinguishes from candidiasis

›Fishy amine odor

›Classically worse after intercourse

›Worse during menses

›Mild vulvovaginal irritation or burning

›Significant pruritus is uncommon in BV

›Prominent pruritus suggests candidiasis

›Absence of alarm symptoms

›No fever or systemic illness

›Fever suggests ascending infection

›Evaluate for PID if present

›No deep pelvic pain or dyspareunia suggesting PID

›No purulent or blood-tinged discharge

›No postcoital bleeding

Timing and triggers

›Episode context

›Onset relative to menstrual cycle

›Odor may worsen with menses

›New or multiple sexual partners as trigger

›Recent exposures

›Vaginal douching

›Recent antibiotic use altering normal flora

›Recurrence pattern

›Three or more documented episodes per year defines recurrent BV

03Physical Exam/exam39

Vitals and general appearance

›Vital sign assessment

›Temperature

›Fever indicates ascending infection or comorbid process

›BV itself is afebrile

›Blood pressure and heart rate

›Hypotension and tachycardia suggest sepsis

›Normal in uncomplicated BV

›General appearance

›Acute distress uncommon in BV

›Pain or toxicity warrants expanded evaluation

Speculum and external exam

›External genitalia

›Typically normal in BV

›Absence of erythema, edema, or excoriations

›Erythema or excoriations suggest candidiasis or contact dermatitis

›Vulvar lesions or ulcers

›Presence mandates HSV and syphilis evaluation

›BV does not cause ulcerations

›Speculum findings

›Thin, homogeneous, grayish-white discharge coating vaginal walls

›Absent or minimal vaginal erythema or inflammation

›Distinguishes from trichomoniasis and candidiasis

›Cervix appearance

›Should appear normal in BV

›Mucopurulent discharge or cervical friability indicates cervicitis

›Strawberry cervix pattern suggests trichomoniasis

04Differential Diagnosis/ddx47

Life threats to exclude first

›Pelvic inflammatory disease

›ICD-10 N73.9

›Fever, cervical motion tenderness, adnexal tenderness

›Must-not-miss ascending infection

›Tubo-ovarian abscess

›ICD-10 N70.93

›Adnexal mass, systemic toxicity

›Ectopic pregnancy

›ICD-10 O00.9

›Pelvic pain and vaginal bleeding in reproductive-age women

›Urine hCG mandatory to exclude

Infectious mimics

›Vulvovaginal candidiasis

›ICD-10 B37.3

›Thick, white, curd-like discharge

›Pruritus predominant symptom

›pH 4.5 or below

›KOH microscopy shows hyphae and budding yeast

›Trichomoniasis

›ICD-10 A59.01

›Green or yellow frothy discharge

›Strawberry cervix on exam

›Motile trichomonads on wet mount

›pH above 4.5

›Cervicitis

›ICD-10 N72

›Mucopurulent cervical discharge

05Laboratory Tests/lt58

Bedside microscopy

›Saline wet mount

›Clue cells on saline microscopy

›Clue cells are epithelial cells studded with bacteria obscuring cell borders

›More than 20% of epithelial cells needed for Amsel criterion

›Sensitivity 60-80% for BV

›Absence of WBCs

›Marked WBCs suggest cervicitis or trichomoniasis

›BV is a noninflammatory condition

›Motile trichomonads

›If present, changes diagnosis to trichomoniasis

›Sensitivity of wet mount for trichomoniasis 60-70% only

›KOH preparation

›Whiff test

›Fishy amine odor with 10% KOH indicates BV

›Positive result counts as Amsel criterion

›Hyphae and budding yeast for candidiasis

›KOH lyses epithelial cells revealing fungal elements

›Negative KOH does not exclude candidiasis

Point-of-care testing

›Vaginal pH measurement

›pH strip or nitrazine paper

›pH above 4.5 supports BV or trichomoniasis

›Sensitivity 97%, specificity 64% for BV

›Semen, cervical mucus, or blood may falsely elevate pH

›Normal pH 3.8 to 4.5 favors candidiasis

›BV unlikely when pH below 4.5

›Useful rapid triage tool

06Diagnostic Tests/dt61

Scoring Systems

›Amsel criteria

›Three of four criteria required for clinical BV diagnosis

›Thin, homogeneous, white-gray discharge

›Clue cells more than 20% on saline microscopy

›Vaginal pH above 4.5

›Positive whiff test with KOH

›Performance characteristics

›Sensitivity 70-87% vs Nugent score reference standard

›Specificity 94-97% when three criteria met

›Practical bedside tool without laboratory equipment

›Nugent scoring system

›Gram stain morphotype scoring

›Score 0-3 normal Lactobacillus dominant flora

›Score 4-6 intermediate category

›Score 7-10 BV diagnosis

›Research and confirmatory role

›Reference standard for epidemiologic studies

›Not required for routine clinical practice

›Recurrent BV classification

›Three or more clinically confirmed episodes per year

›Warrants suppressive therapy protocol

›StepUp RCT data supports male partner co-treatment in this group

MRI

›MRI pelvis indications

›Not indicated for uncomplicated BV

›BV is a clinical and microbiologic diagnosis

›MRI reserved for structural or malignant pathology

07Disposition/dispo37

Discharge criteria

›Outpatient management criteria

›Uncomplicated BV is managed entirely as outpatient

›No systemic infection features

›No concern for PID or TOA

›Ability to take oral medications

›No persistent vomiting

›Reliable adherence plan with counseling provided

›Appropriate follow-up plan

›Routine test-of-cure not required if symptoms resolve

›Return in 3 months if symptoms recur given recurrence rate up to 30% at 3 months

Admission indications

›Criteria for hospital admission

›Concurrent PID with systemic toxicity

›Fever, peritoneal signs, or inability to tolerate oral medications

›IV antibiotics required

›Suspected tubo-ovarian abscess

›Requires IV therapy and surgical backup

›Failure of IV therapy may require drainage or surgery

›Inability to tolerate oral medications

›Hyperemesis or severe GI intolerance

›Alternative IV or intravaginal formulation needed

Referral and follow-up

›Specialist referral indications

›OB/GYN referral

›Recurrent BV refractory to standard suppressive therapy

›Diagnostic uncertainty after initial evaluation

›Infectious disease referral

08Treatment/t82

First-line antibiotic regimens

›Oral metronidazole

›Metronidazole 500 mg PO twice daily for 7 days

›Most commonly used first-line regimen

›CDC 2021 and ACOG Practice Bulletin 215 recommendation

›GI side effects including nausea common

›Evidence for disulfiram-like reaction with alcohol is lacking per CDC 2021

›Completion counseling

›Complete full 7-day course

›Avoid vaginal intercourse during treatment to improve cure rates

›Intravaginal metronidazole gel

›Metronidazole gel 0.75%, one applicator (5 g) intravaginally daily for 5 days

›Superior GI tolerability compared to oral formulation

›CDC 2021 first-line alternative

›Systemic absorption minimal

›Patient instructions

›Avoid tampons during intravaginal treatment

›Applicator reuse instructions per product labeling

›Intravaginal clindamycin cream

›Clindamycin cream 2%, one applicator (5 g) intravaginally at bedtime for 7 days

›CDC 2021 first-line alternative

›Oil-based formulation weakens latex condoms and diaphragms for 5 days after use

›Patients must be counseled on contraceptive failure risk

Alternative antibiotic regimens

›Secnidazole

›Secnidazole 2 g PO as a single dose

›CDC 2021 alternative regimen

›Convenient single-dose administration improves adherence

›Limited data in pregnancy and lactation

›Tinidazole regimens

›Tinidazole 2 g PO once daily for 2 days

›CDC 2021 alternative

›Or tinidazole 1 g PO once daily for 5 days

›Avoid in pregnancy particularly first trimester

›Oral clindamycin

›Clindamycin 300 mg PO twice daily for 7 days

›CDC 2021 alternative

›Higher C. difficile risk than metronidazole

›Reserve for metronidazole intolerance

›Clindamycin ovules

›Clindamycin ovules 100 mg intravaginally at bedtime for 3 days

›CDC 2021 alternative

›Oil-based, same latex contraceptive warning as cream

›Shorter duration than cream formulation

Recurrent BV management

›Acute treatment of recurrent episode

›Extended oral metronidazole 500 mg PO twice daily for 10-14 days

›Longer initial course before suppression

›Based on expert consensus and clinical guidelines

›Followed by suppressive therapy

›Metronidazole gel 0.75% twice weekly for 3-6 months

›Reduces recurrence frequency

›ACOG and AAFP supported approach

›Male partner treatment for recurrent BV

›Concurrent male partner treatment regimen

›Oral metronidazole 400 mg PO twice daily for 7 days

›Topical 2% clindamycin cream applied to penile skin twice daily for 7 days

›Evidence: StepUp RCT (NEJM 2025)

›Reduced BV recurrence from 63% to 35% at 12 weeks

›HR 0.37, 95% CI 0.22-0.61, P less than 0.001

›ACOG now advises considering partner therapy for recurrent BV

›Emerging therapies for recurrent BV

›Lactin-V live biotherapeutic product

›Lactobacillus crispatus vaginal capsule under investigation

›Phase 2 data showing reduced recurrence

›Vaginal microbiota transplantation

›Experimental; not yet in standard clinical practice

›Active research area per Current Opinion in Infectious Diseases 2026

Supportive measures and counseling

›Behavioral modifications

›Cessation of vaginal douching

›Strongly recommended to prevent recurrence

›Disrupts normal Lactobacillus flora

›Condom use or abstinence during treatment

›Reduces reinfection or dysbiosis

›Avoid latex condoms with oil-based intravaginal products

›Avoid scented soaps and intravaginal products

›pH alteration promotes dysbiosis

›Unscented external washing only

›Asymptomatic BV

›Treatment not recommended for asymptomatic nonpregnant women

›USPSTF recommendation against routine screening

›Exception: pre-procedural BV treatment before hysterectomy or IUD insertion

›Asymptomatic BV in pregnancy

›Treatment recommended for symptomatic pregnant women

›Evidence for treating asymptomatic pregnant women for preterm birth prevention is insufficient per USPSTF 2020

09Special Populations/sp61

Pregnancy

›BV in pregnancy overview

›Prevalence approximately 15-20% in pregnant women

›Associated with significant maternal and fetal complications

›2-fold increased risk of preterm birth (OR 1.76-2.19)

›Increased risk of PROM (OR 2.59), miscarriage (OR 2.34), and postpartum endometritis

›Treatment threshold

›Treat all symptomatic pregnant women

›USPSTF 2020: insufficient evidence to recommend universal screening for prevention of preterm birth

›Safe antibiotic regimens in pregnancy

›Oral metronidazole preferred in pregnancy

›Metronidazole 500 mg PO twice daily for 7 days

›Or metronidazole 250 mg PO three times daily for 7 days

›Safe in all trimesters based on reassuring data

›CDC 2021 recommendation

›Agents to avoid in pregnancy

›Tinidazole: avoid due to insufficient safety data

›Secnidazole: insufficient data in pregnancy

›Clindamycin cream: theoretical concern for fetal harm with systemic absorption

›Monitoring and follow-up in pregnancy

›Test of cure one month after treatment

›Recurrence common in pregnancy

›Repeat treatment if recurs

›MFM referral for prior preterm birth with recurrent BV

›High-risk obstetric co-management

›Consider cerclage and progesterone as adjuncts per obstetric team

Geriatric

›Epidemiology in older adults

10Background/b73

Epidemiology

›Prevalence and burden

›Most common cause of abnormal vaginal discharge in reproductive-age women

›Accounts for 40-50% of identified vaginitis cases

›Approximately 5-10 million US office visits annually

›Worldwide prevalence estimated at 23-29% in reproductive-age women

›Prevalence varies by population

›Higher prevalence in Black, Hispanic, and Mexican American women

›Higher rates in sub-Saharan Africa (up to 50%)

›Higher rates in women who have sex with women

›Recurrence burden

›Up to 50% recurrence rate within 12 months of treatment

›Up to 30% recurrence within 3 months

›Recurrent BV defined as three or more episodes per year

›Asymptomatic BV

›Approximately 50% of women with BV are asymptomatic

›Prevalence suggests vast underdiagnosis

Pathophysiology

›Microbial dysbiosis mechanism

›Replacement of Lactobacillus-dominant flora

›Normal vaginal pH 3.8-4.5 maintained by lactic acid from Lactobacillus

›Loss of Lactobacillus crispatus and Lactobacillus iners colonization

›Overgrowth of anaerobes and facultative bacteria

›Key organisms in BV

›Gardnerella vaginalis as key initiating organism

›Prevotella, Bacteroides, and Atopobium vaginae (Fannyhessea vaginae) also present

›Mobiluncus and Mycoplasma hominis associated species

›Polymicrobial biofilm formation

›G. vaginalis forms primary biofilm on vaginal epithelium

›Biofilm protects organisms from antibiotics and host defenses

›Explains high recurrence rates after antibiotic treatment

›Inflammatory profile

›BV is noninflammatory compared to candidiasis and trichomoniasis

›Absence of significant WBCs on wet mount

›No significant mucosal erythema or edema

›Amine production

›Anaerobic metabolism produces volatile amines

›Trimethylamine and putrescine cause characteristic fishy odor

›Amines volatilize with alkaline pH explaining worse odor after intercourse and menses

›Sexual transmission evidence

›Growing evidence for sexual transmission

›Concordant G. vaginalis strains detected in sexual partners

›Higher rates in women with new partners and more partners

›StepUp RCT demonstrated male partner treatment reduces recurrence

Therapeutic Considerations

›Antibiotic mechanism and limitations

›Metronidazole and tinidazole mechanism

›Nitroimidazoles with activity against anaerobes and some G. vaginalis strains

›Disrupts DNA of susceptible organisms via free radical generation

›Limited biofilm penetration contributes to recurrence

›Clindamycin mechanism

›Lincosamide antibiotic with broad anaerobic coverage

›Bacteriostatic at low concentrations

›Higher C. difficile risk limits routine use

›Recurrence biology and suppression rationale

›Biofilm persistence after antibiotic treatment

›Surface biofilm clears with antibiotics

›Deep biofilm layers remain viable and reseed vaginal flora

›Suppressive vaginal metronidazole gel reduces biofilm reseeding

›Role of Lactobacillus restoration

›Antibiotics do not directly restore Lactobacillus

›Natural Lactobacillus recolonization takes weeks to months

›Live biotherapeutics under development target this gap

›Evidence base for key decisions

›ACOG Practice Bulletin 215 (2020): comprehensive management guidance

›Amsel criteria or Nugent score for diagnosis

›First-line regimens include three equivalent options

›CDC 2021 STI Treatment Guidelines

›Specific drug, dose, and duration recommendations

›Partner treatment for recurrent BV supported by emerging data

›StepUp RCT (NEJM 2025)

›Landmark trial demonstrating partner treatment efficacy

›Changed practice for recurrent BV management

›USPSTF 2020

›Insufficient evidence to screen asymptomatic pregnant women for BV prevention of preterm birth

›Grade I recommendation

11Patient Discharge Instructions/pdi40

copy discharge instructions

›What you have been diagnosed with

›Bacterial vaginosis (BV)

›An imbalance of the normal bacteria in your vagina

›Not a sexually transmitted infection, but linked to sexual activity

›Very common and treatable

›Your medication instructions

›If prescribed metronidazole (Flagyl) pills

›Take 500 mg twice daily for 7 days

›Take with food to reduce nausea

›Complete the entire course even if symptoms improve early

›If prescribed metronidazole vaginal gel

›Insert one applicator into the vagina once daily for 5 days

›Use at bedtime for comfort

›Avoid tampons during treatment

›If prescribed clindamycin vaginal cream

›Insert one applicator at bedtime for 7 days

›Do not use latex condoms for 5 days after finishing; the cream can weaken them

›Things to avoid during treatment

›Vaginal douching

›Douching disrupts bacteria and increases recurrence

›Never recommended

›Scented soaps, sprays, or products in vaginal area

›Irritate the lining and disrupt normal flora

›Sexual intercourse during treatment

›Reduces reinfection risk and improves cure rates

›When to return to the emergency department

›Fever above 38.5 C or chills

12References/r38

Guidelines and key sources

›Primary guidelines

›CDC Sexually Transmitted Infections Treatment Guidelines 2021

›Workowski KA et al. MMWR Recomm Rep. 2021

›First-line and alternative regimens for BV

›ACOG Practice Bulletin Number 215: Vaginitis in Nonpregnant Patients (2020)

›Committee on Practice Bulletins-Gynecology. Obstet Gynecol. 2020

›Diagnostic criteria and management framework

›USPSTF Recommendation: Screening for BV in Pregnant Persons (2020)

›JAMA 2020. Owens DK, Davidson KW et al.

›Grade I: insufficient evidence for universal screening

Landmark trials and reviews

›Clinical trials

›StepUp RCT: Male-Partner Treatment to Prevent Recurrence of BV

›Vodstrcil LA, Plummer EL, Fairley CK et al. NEJM 2025

›Male partner treatment reduced BV recurrence from 63% to 35% at 12 weeks

›NEJM Review: Bacterial Vaginosis and Desquamative Inflammatory Vaginitis

›Paavonen J, Brunham RC. NEJM 2018

›Pregnancy complications and pathophysiology overview

›Systematic reviews and meta-analyses

›Maternal and fetal outcomes with BV in pregnancy

›Kenfack-Zanguim J et al. Eur J Obstet Gynecol Reprod Biol. 2023

›OR 1.76-2.19 for preterm birth, OR 2.59 for PROM

›Microbiology laboratory diagnostic guidance

›Miller JM et al. Clin Infect Dis. 2024 IDSA/ASM update

›NAAT performance characteristics for vaginitis pathogens

Diagnostic and coding references

›Diagnostic codes

Learn More: Vaginitis (Bacterial)→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.